You are seeing these quotes based on previous browsing related to sectors such as
Latest | Forecast | |
---|---|---|
Div Yield | 0.0% | n/a |
Div Cover | n/a | n/a |
Op Mrgn | -95.6% | n/a |
ROCE | 0.0% |
Latest | Forecast | |
---|---|---|
P/E | -8.6 | n/a |
PEG | 0.0 | n/a |
Price / Revenue | 7.5 | n/a |
Price / Book value | 5.0 |
Latest | Forecast | |
---|---|---|
Revenue | 11,761.9% | 11.5% |
PBT | 0.0% | n/a |
EPS | 0.0% | 44.1% |
DPS | n/a | 0.0% |
Year Ending | Revenue ($m) |
Pre-tax ($m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
---|---|---|---|---|---|---|---|---|
2018-12-31 | 214.11 | -86.65 | $-0.01 | -405.6 | 0.0 | n/a | n/a | 0.0% |
2019-12-31 | 204.89 | -141.10 | $-0.16 | -31.5 | 0.0 | n/a | n/a | 0.0% |
2020-12-31 | 227.98 | -189.73 | $-0.18 | -34.9 | 0.0 | n/a | n/a | 0.0% |
2021-12-31 | 356.13 | -215.74 | $0.00 | -2,840.3 | 0.0 | n/a | n/a | 0.0% |
2022-12-31 | 426.41 | -410.42 | $-0.43 | -7.4 | 0.0 | n/a | n/a | 0.0% |
Hutchmed confirms new drug application for fruquintinib in Japan Sharecast News | 29 Sep |
---|---|
Director dealings: IPF non-exec picks up shares, Hutchmed China director linked to sale Sharecast News | 14 Sep |
Hutchmed reports progress on two oncology fronts Sharecast News | 12 Sep |
Total Voting Rights | 30-Nov-23 08:38 |
---|---|
U.S. FDA Approval of FRUZAQLAâ„¢ (fruquintinib) | 09-Nov-23 07:01 |
Vesting of awards under the LTIP | 24-Oct-23 09:30 |
Total Voting Rights | 29-Sep-23 11:37 |
Director’s Share Dealing | 14-Sep-23 17:36 |